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Background: Adjuvant chemotherapy (AC) improves survival among patients with operable breast cancer.
However, the effect of delay in AC initiation on survival is unclear. We performed a systematic review and meta-
analysis to determine the relationship between time to AC and survival outcomes.
Methods: PubMed, EMBASE, Cochrane Database of Systematic Reviews, and Web-of-Science databases (between
January-1 1978 and January-29, 2013) were searched for eligible studies. Hazard ratios (HRs) for overall survival (OS)
and disease-free survival (DFS) from each study were converted to a regression coefficient (β) corresponding to a
continuous representation per 4-week delay of AC. Most used regimens of chemotherapy in included studies were
CMF (cyclophosphamide, methotrexate, and fluorouracil) or anthracycline-based. Individual adjusted β were
combined using a fixed-effects or random-effects model depending on heterogeneity.
Results: We included 7 eligible studies with 9 independent analytical groups involving 34,097 patients, 1 prospective
observational study, 2 secondary analyses in randomized trials (4 analytical groups), and 4 hospital-/population-based
retrospective study. The overall meta-analysis demonstrated that a 4-week increase in time to AC was associated
with a significant decrease in both OS (HR = 1.15; 95% confidence interval [CI], 1.03-1.28; random-effects model)
and DFS (HR = 1.16; 95% CI, 1.01-1.33; fixed-effects model). One study caused a significant between-study
heterogeneity for OS (P < 0.001; I2 = 75.4%); after excluding that single study, there was no heterogeneity
(P = 0.257; I2 = 23.6%) and the HR was more significant (HR = 1.17; 95% CI, 1.12-1.22; fixed-effects model). Each single
study did not fundamentally influence the positive outcome and no evidence of publication bias was observed in OS.
Conclusions: Longer time to AC is probably associated with worse survival in breast cancer patients.Background
Breast cancer is one of the most common cancers in
women in both developed and developing countries.
Several large clinical trials and meta-analysis of all the
relevant randomized trials of adjuvant systemic therapy
have consistently demonstrated that chemotherapy de-
creases 30-40% risk of breast cancer mortality versus
those without chemotherapy [1]. Adjuvant chemother-
apy (AC) is routinely recommended to most of breast* Correspondence: yukd@shca.org.cn; zhimingshao@yahoo.com
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reproduction in any medium, provided the orcancer patients post surgeries. National Comprehensive
Cancer Network guidelines (www.nccn.org) recommend
patients with tumor larger than 1 cm or having involved
nodes to receive AC; while St. Gallen consensus recom-
mends patients with endocrine non- or less-responsive
disease to undergo AC [2]. Clinically, 60-80% of breast
cancer patients would ultimately receive AC, but the
optimal time from surgery to the start of chemotherapy
is unclear albeit clinicians have used chemotherapy in
breast cancer for more than a half century. Oncologists
might suggest start of AC within 6 to 8 weeks after
surgery based on a routine clinical assumption that AC
should commence as soon as practical. Some clinicians
might also harbor the assumption that chemotherapyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of 3 months [3]. However, there is no direct evidence
supporting either of these assumptions. Of note, in prac-
tice, not all patients could initiate AC in this time frame,
and some have to face a delay in AC due to postopera-
tive complications, personal decision of receiving AC,
comorbid conditions, or health-system logistic factors
such as delays in referral or waiting times.
Time window of AC treatment remains an important
issue. Regrettably, this issue has not been subjected to a
randomized controlled clinical trial; nor is such trial
likely to be undertaken due to its low operability, poor
patient compliance, and potential ethical problems. Sev-
eral retrospective studies [4-7], observational prospective
studies [8], and retrospective analyses on clinical trial
data [9,10], have examined the impact of early and de-
layed initiation of AC on survival of breast cancer pa-
tients, but the results are inconsistent. To address this
important gap, we undertook a systematic review of all
the relevant literatures and performed a quantitative
meta-analysis to assess the relationship between a delay
in AC and survival in breast cancer.
Methods
Literature search
The literature search was conducted in the PubMed,
EMBASE, Cochrane Database of Systematic Reviews,
and Web-of-Science databases (between January-1 1978
and January-29 2013). Potentially relevant studies were
identified using following keywords: “(Timing or time)
and adjuvant and (chemotherapy or chemotherapeutic)
and breast cancer and survival”. The reference lists from
relevant papers, especially from review articles, were
checked to identify more studies unidentified in the
original search. Online available abstracts of the annual
meetings of the American Society of Clinical Oncology
(2007–2011) were searched for newly completed studies.
This systematic review and meta-analysis was planned,
conducted, and reported in adherence to the standards
of quality for reporting meta-analysis [11]. The basic
procedure of meta-analysis was performed as described
previously [12-14].
Eligibility and validity of literature-based data
The citations from the initial search were subsequently
screened for eligibility. Studies included in the system-
atic review and meta-analysis should meet the following
criteria: (1) All patients with operable primary breast
cancer were treated with AC, with documented time
from surgery to initiation of AC. (2) The relationship be-
tween time interval from surgery to AC and patient out-
comes in breast cancers was reported. The outcomes
could be presented as disease-free survival (DFS), event-
free survival (EFS), relapse-free survival (RFS), or overallsurvival (OS). Hazard ratio (HR) with 95% confidence
intervals (CIs) (or sufficient data to calculate them) was
reported. (3) To minimize the effect of confounding be-
tween comparison groups, only studies identified as
“high validity” by the following criteria were included in
the pooling analysis: first, the relevant prognostic factors
were adequately described between comparator groups;
second, either the comparison groups were balanced for
the relevant prognostic factors, or the reported results
were adjusted for other prognostic factors [13]. (4) Studies
that used nonstandard forms of AC (e.g., perioperative,
dose-dense, or neoadjuvant chemotherapy), or examined
the effect of concurrent or sequencing of additional adju-
vant therapies (e.g., endocrine therapy or radiotherapy)
were excluded. (5) To reduce the effect of publication bias,
all publish types either full-text article, correspondence, or
meeting abstract were eligible. But studies should be
published in English. Three reviewers (Y.K.D., H.S., and
S.Z.M.) independently assessed studies for inclusion
with disagreements resolved by consensus. The study
quality was assessed using the 9-star Newcastle-Ottawa
Scale (The Newcastle-Ottawa Scale for assessing the
quality of nonrandomized studies in meta-analyses.
Ottawa, Canada: Dept of Epidemiology and Community
Medicine, University of Ottawa. http://www.ohri.ca/
programs/clinical_epidemiology/oxford.htm. Accessible
on March-1, 2013).
Estimating HR for adverse outcomes per 4-week delay
in AC
This step was mainly performed according to the pro-
cedure described previously with a few modifications
[13,14]. Briefly, the measure of effect in all studies was a
HR for OS and/or DFS. In most studies, EFS or RFS had
the same or similar definition to DFS and thus was
treated as DFS when appropriate. The eligible studies
used disparate categorical representations of waiting
time. To provide a common representation for synthesis
of the results of individual studies, we converted the
waiting time effect size to a regression coefficient (β)
and its standard error (SE) corresponding to a continu-
ous representation per 4-week of delay. For the waiting
time categories in each article, a central value was
assigned to each category. For studies with 2 waiting
time groups, since the authors defined the 2 groups as
“before n weeks (not delayed AC)” and “after n weeks
(delayed AC)”, we treated the reference time level as
n/2 weeks and the exposure time level as n/2 + n weeks.
the weekly β was calculated as ln(HR)/(Xn −X0), and the
corresponding SE of β was calculated as (ln[upper of
95% CI]-ln[lower of 95% CI])/([Xn − X0]*1.96*2), where
CI is confidence interval, Xn denotes exposure at N
level by time (week), and X0 denotes exposure at reference
time level. We transferred all time unit (day, week, or





to January-29 2013 
24 Papers retrieved
5 Studies identified from reference,
citations, and abstract search
1067 Excluded based on screening of title
66 Excluded based on screening of abstract
29 Papers reviewed for inclusion
and validity criteria
90 Papers further evaluated
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number of week. The value of 1.96 might change according
to the significance level in each study. If only a P-value was
provided, the SE was calculated as the “test-based” method:
SE of ln(HR) = (ln[HR])/Zp, where Zp is the value of a unit-
normal test (e.g., Zp = 1.96 when P = 0.05, 2-sided test). For
the studies with more than 2 categories, the weighted
least-squares linear regression of the ln(HR) on every ex-
posure level in one study was used to estimate the sum-
mary β as previously described [15,16]. The dependent
variable for the regression was the log of each study-
specific HR, weighted by the inverse of its variance. The
summary measures of HR per 4-week of delay from each
study presented here can be interpreted as the incidence
rate ratio for the outcome with each 4-week of additional
waiting for AC, which could be calculated by eβ*4. We
made all the above calculations assuming a log linear rela-
tionship between HR and delayed time.22 Excluded for reasons: 
7 Low validity





7 Studies eligible (a total of 9 independent analytical 
groups*):
7 Overall survival*
2 Disease-free survival 
Figure 1 The literature search process. Validity required that
either the comparison groups were balanced for relevant prognostic
factors or the reported results were adjusted for these prognostic
factors (Refer to the “Methods” section). *One study includes 3
analytical groups in overall survival.Meta-analysis
The adjusted regression coefficients from individual
studies were combined using a fixed-effects or random-
effects model according to absence or presence of
between-study heterogeneity, respectively. Q statistic
and I2 were used to evaluate the statistical heterogeneity
between studies [17]. Heterogeneity was considered as
either a P-value <0.05 or I2 >25% [18]. The inverse vari-
ance was used to weight individual studies. We
performed influence analysis (sensitivity analysis) by
omitting each study to find the potential outliers. The
potential publication bias was examined visually in a
funnel plot of log(HR) against its SE, and the degree of
asymmetry was tested using Egger’s test [19] (P < 0.05
considered to be statistically significant). All of the stat-
istical analysis was performed using Stata v.10.0 (Stata
Corporation, College Station, TX) and SPSS 17.0 (SPSS
Inc, Chicago, IL). Two-sided P < 0.05 was considered sta-
tistically significant.Results
The flow diagram of literature search is shown in Figure 1.
The search strategy yielded 1,157 reports, of which 29
were potentially eligible after reviewing their abstracts.
Twenty-one items were further excluded either because of
a lack of data or because they did not meet the high valid-
ity criteria, leaving 7 eligible papers including 7 independ-
ent analytical groups for OS and 2 for DFS, respectively
(Table 1). The studies were published between 1989 and
2013. There were 34,097 patients with primary breast
cancer, with a range of sample size from 229 to 14,380.
Two studies (4 analytical groups) reported time to AC data
as a secondary analysis within randomized controlled trials
of chemotherapy treatment [9], 1 study was conductedprospectively [8,10], and the left 4 were retrospective inves-
tigations using hospital- or population-based data [5-7,20].
The HR results from individual eligible studies listed
in Table 1 are plotted in Figure 2A, which shows the
HRs for categorical representations of waiting time in
the 7 studies for OS. The waiting times covered by the
studies ranged from 2 to 12 weeks. This figure illustrates
that HRs at different waiting time were similar and
therefore supports conversion of HRs from categories to
an HR for a continuous representation by waiting time.
For each study, a single HR corresponding to the relative
increase in mortality risk with each additional 4-week of
waiting time was extracted (Figure 2B). For studies con-
trasting 2 waiting time categories, the line was the same
as that presented in Figure 2A. For studies using more
than 2 categories, the HR was estimated using meta-
regression. The 4-folds of slope of each line (by log
converted HR) in Figure 2B represented the log of final
HR used in meta-analysis (i.e., HR per 4-week of delay).
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Reference 28-42 days 883 9-yr DFS
58%
>42 days 105 9-yr DFS
49%
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OS, 0.929 (0.441-1.957) 3-4 wks 92
OS, 1.549 (0.761-3.149) 4-5 wks 75
OS, 1.588 (0.856-2.948) 5-13 wks 127
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Table 1 Characteristics of eligible studies on waiting time to adjuvant chemotherapy and survival in breast cancer (Continued)
















Reference 1-3 wks 188
OS, 1.218 (0.800-1.854) 3-4 wks 305
OS, 1.045 (0.716-1.525) 4-5 wks 263
OS, 1.238 (0.861-1.782) 5-13 wks 328
Hershman















Reference <1 month 2,361
OS, 1.00 (0.88-1.14) 1-
2 months
1,846
OS, 1.08 (0.85-1.36) 2-
3 months
323
OS, 1.46 (1.21-1.75) >3 months 477
Lohrisch et al.
[7] 2006
USA (Retros.,) 47 yr Mixed I-II 60.0 CMF and Anthr.-
based




Reference ≤4 wks 993 5-yr EFS
72.7%; 5-yr
OS 83.5%
4-8 wks 1,272 5-yr EFS
77.3%; 5-yr
OS 85.1%
8-12 wks 217 5-yr EFS
82.0%; 5-yr
OS 88.7%





















Reference ≤3 months 12,748
OS, 1.53 (1.32–1.80) >3 months 1,632
DSS, 1.83 (1.31–2.47) >3 months 1,632
Abbreviations: Anthr, Anthracycline; BCCA, British Columbia Cancer Agency; CI, Confidence interval; CMF, Cyclophosphamide, methotrexate, and fluorouracil; CT, Clinical trial; DBCG, Danish Breast Cancer Cooperative
Group; DFS, Disease-free survival; DSS, Disease-specific survival; EFS, Event-free survival; FASG, French Adjuvant Study Group; FU, Follow up; HR, Hazard ratio; IBCSG, International Breast Cancer Study Group; LN+, Lymph
nodes positive; NR, Not reported; OS, Overall survival; Post, Postmenopausal; Pre, Premenopausal; Pros, Prospective study; Retro, Retrospective study; RFS, Relapse-free survival; SEER, The Surveillance, Epidemiology, and
End-Results database; WT, Waiting time.
*The publish type of this study is a meeting abstract.
§Analysis performed in patients receiving chemotherapy only.



























































Figure 2 Individual hazard ratio for overall survival according
to waiting time categories. A. The relationship between waiting
time categories and overall survival in the 7 independent analytical
groups. The hazard ratio (HR) represents a comparison with the
lowest waiting time category in each study (as reference). The first
author of each study is shown. B. Conversion of HR estimates from
the original studies to an HR per week of delay. The slope of each
line represents the change in the log HR per week delay. The line
for each individual study is located over the range of waiting times.
The thick line indicates the weighted average of the HRs from the
individual studies. The vertical axis is on a log scale.
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http://www.biomedcentral.com/1471-2407/13/240Figure 3A presents the forest plot of meta-analysis for
OS, including HRs and 95% CIs per 4-week of delay for
7 analytical groups. The combined HR was 1.15 (95% CI,
1.03-1.28; P = 0.009) by random-effects model. There
was statistically significant heterogeneity between studies
of OS (P < 0.001; I2 = 75.4%). To explore the resource of
heterogeneity, we performed influence analysis, which
omits one study at a time and calculates the recombined
HRs for the remainders. It showed that the Cold-II study
by Cold et al. [10] substantially influenced the pooled HR
(Figure 3B). After excluding that single study, there was
no between-study heterogeneity (P = 0.257; I2 = 23.6%),
and the HR was more significant (HR = 1.17; 95% CI,
1.12-1.22; P < 0.001; fixed-effects model). To further test
the robustness of our study, we alternatively removed 2
studies with the largest weight and recalculated acombined HR estimate from the remaining studies,
consistent and statistically significant results were
maintained. The HR after removal of the Cold-II study by
Cold et al. [10] (25.08% weight) and the study by
Nurgalieva et al. [20] (26.09% weight) was 1.23 (95% CI,
1.12-1.34; fixed-effects model) without evident hetero-
geneity either (P = 0.284, I2 = 20.5%). The funnel plot
was used to evaluate publication bias and the Egger’s
test showed no evidence of publication bias (P = 0.351).
The analyses were repeated for DFS (forest plot shown
in Figure 4). The relevant 2 studies included 4,390 breast
cancer patients. The combined HR was 1.16 (95% CI,
1.01-1.33; fixed-effects model), without evidence of het-
erogeneity (P = 0.623, I2 = 0.0%).
Discussion
Adjuvant chemotherapy (AC) has been admitted as the
standard treatment for most breast cancer patients.
However, the exact time frame of AC treatment initiated
post-surgery to gain maximal benefit still remains un-
clear. The published clinical trials do not specifically
suggest the timing of chemotherapy after surgery, and
there is a wide variation across trials in the allowed time
between surgery and AC, ranging from 2 to 12 weeks
[21-24]. It is unlikely that there will be additional pro-
spective clinical trials comparing outcomes for AC initi-
ation before or after a specified time (not perioperative)
from surgery. Therefore, we have to rely on retrospective
data as reviewed in this study. In this report, the system-
atic review and meta-analysis indicate that OS decreases
by 15% for every 4-week delay in initiation of AC. Our
results are also consistent across DFS analysis. This
present study is the first fully-reported meta-analysis spe-
cifically addressing the effect of a delay in time to AC on
survival outcomes in breast cancer in a quantitative way.
The effect of AC on survival is thought to be eradication
of micrometastatic deposits in a proportion of patients.
There is a substantial theoretical rationale to initiate AC
immediately after curative surgery. Investigation in animal
models has demonstrated that surgery may increase the
numbers of circulating tumor cells and oncogenic growth
factors, and accelerate growth of metastases [25,26]; a sin-
gle dose of chemotherapy given early seemed more effi-
cient than treatment given later [27]. Biological plausibility,
clinical observations, and published studies have brought
up a comprehensive hypothesis that early initiation of AC
is clinically crucial to patient’s survival.
The available evidence that describes a relationship be-
tween time to AC and patient outcomes is shown in
Table 1. In other relevant studies of association between
time to AC and survival but not included in this meta-
analysis due to low validity, inconsistent results were
presented. Studies by Buzdar et al. [28], Shannon et al.





Cold et al. 2005 (III)
Hershman et al. 2006
Lohrisch et al. 2006
Cold et al. 2005 (II)
Pronzato et al. 1989
Cold et al. 2005 (I)
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Nurgalieva et al. 2013 1.15 (1.09, 1.21)









1.00 1.151.03 1.28 1.37
Pronzato et al. 1989
Cold et al. 2005 (I)
Cold et al. 2005 (II)
Cold et al. 2005 (III)
Hershman et al. 2006
Lohrisch et al. 2006
Nurgalieva et al. 2013
Lower CI Limit Estimate Upper CI Limit
Given named study is omitted
Figure 3 Individual study and overall hazard ratios of relationships between every 4-week delay in initiation of adjuvant
chemotherapy and overall survival. Individual and overall hazard ratios (HR) per 4-week of delay with 95% confidence interval (CI) for OS are
shown in A. The size of each square is proportional to the weight of the study. For the combined result, the length of the diamond represents
the 95% CI of the summary. B. shows the influence of individual studies on the pooled HR. The vertical axis indicates the overall HR and the two
vertical axes indicate its 95% CI. Every hollow round indicates the pooled OR when the left study is omitted in this meta-analysis. The two ends
of every broken line represent the respective 95% CI.
Kerbrat, et al. 2005











Hazard Ratio per 4-wk
of Delay (95% CI) Weight %
Figure 4 Individual study and overall hazard ratios of relationships between every 4-week delay in initiation of adjuvant
chemotherapy and disease-free survival. Individual and overall hazard ratios (HR) per 4-week of delay with 95% confidence interval (CI) for
DFS is shown. The size of each square is proportional to the weight of the study. For the combined result, the length of the diamond represents
the 95% CI of the summary.
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surgery compared with chemotherapy stared early. In con-
trast, Alkis et al. [31] reported that OS was significantly
better in patients who started AC within 44 days. Brooks
et al. [32] also exhibited an improvement in DFS for pa-
tients with node-positive cancers receiving AC within
4 weeks compared with those patients receiving delayed
chemotherapy. Another Turkish study [33] argued that
the upper limit of time to initiation of AC could be up to
4.8 months. We did not included all the aforementioned
studies [4,28-33] since none of them have provided suffi-
cient data to calculate an adjusted and quantitive HR for
meta-analysis. Biagi et al. [34] also performed a similar
meta-analysis and demonstrated that a 4-week increase in
time to adjuvant chemotherapy was associated with a sig-
nificant OS HR of 1.06 (95% CI 1.02-1.10) and DFS HR of
1.08 (95% CI 1.03-1.14) in breast cancer. However, that
study published abstract only in ASCO 2011, and there
was a statistical flaw because the authors combined indi-
vidual studies using a fixed-effect model although there
was an obvious inter-study heterogeneity.
Our meta-analysis demonstrates an evident association
between delayed AC and poor OS. However, there was a
significant heterogeneity between studies for OS. By influ-
ence analysis, a study (Cold-II) based on clinical trial data
[10] seemed to be a major resource of heterogeneity. After
removing that single study, the heterogeneity disappeared
and the association was more significant. The disparate re-
sults before and after removing the Cold-II study [10] may
be due to the relative short waiting times of that study (all
the patients from controlled trials and received AC within
3-months after surgery), patient selection bias (women
with delayed AC could not be enrolled in original trials),
inappropriate category classification (investigator grouped
the patients into 1–3 weeks, 4 weeks, 5 weeks, and 6–
13 weeks group; such short intervals make detection of
significance difficult), and possibly, the cycle numbers of
chemotherapy (they used CMF i.v. on day 1, every 3 weeks,
9 times; while classical CMF used on days 1 and 8, every
4 weeks, 12 times).
Applying our findings to a patient who is ready to initiate
AC at 4 weeks after surgery but is actually delayed, this
patient would have a 15% increased risk of mortality if
treated at 8 weeks and 32.25% increased risk at 12 weeks.
According to the updated EBCTCG report, 36% reduction
in breast cancer mortality rate can be achieved for AC ver-
sus no AC at 10-year [1]. We may reckon that, in general,
breast cancer patients should start AC with no more than
8-week delay of the planned initiation which is probably
within 4 weeks after surgery. However, for the high-risk pa-
tients with young age and ER-negative tumor, individual-
ized strategy of AC initiation should be applied according
to relevant study [9]. Although our analysis may over- or
under-estimate the effect of delayed time on survival, webelieve these results should help to modify protocols for
those agencies that carry breast cancer cares and services.
Some limitations should be declared. First, our meta-
analysis is limited by the nonrandomized and retrospective
nature of the included studies. However, it is unrealistic to
expect that a randomized trial of time to AC will ever be
done; rather, analyses such as ours are likely to provide the
only evidence of such an effect. Hence we believe that our
results, coupled with preclinical models and relevant clin-
ical evidence, have provided sufficient proof of a substan-
tial reverse relationship between prolonged waiting times
to initiation of AC and reduced survival. Second, there
should be other prognostic factors not controlled in the
meta-analysis. The number of cycles, completion rate for
AC, dose reduction, using endocrine therapy or not, and
HER2 status, which were considered as key determinants
of survival, are not always adjusted in the eligible studies.
The effect of AC delay on survival might vary in patients
with different clinicopathological features. However, be-
cause of a lack of individual information of patients, we
failed to do sub-analyses according to different features.
Third, at least 57% of all the study patients (according to
Hershman’s [6] and Nurgaliev’s [20] studies) were older
than 65 years. The different age distribution of the patients
between this study and general breast cancer population
(median age is 55 years according to SEER database [35])
might have potential impacts on the conclusion. Fourth,
our study relies on the assumption of a log-linear rela-
tionship for the effect of waiting time on survival. How-
ever, the assumption of linearity to this relationship might
be problematic sometimes. For instance, a few studies
showed that survivals were similar for patients if they
started AC within 12 weeks after surgery, and only those
starting AC at later than 12 weeks had significantly infer-
ior survival [6,7]. Since a linear relationship may unfit the
first 12 weeks, the regressed summary HR across the
whole time frame may not reflect the real effect. Finally,
since most included studies used CMF and anthracycline-
based regimen, whether the results of meta-analysis can
be extrapolated to the current taxane era is unclear. Al-
beit this, our findings might potentially have broad clin-
ical relevance. Since removal of a primary tumor would
enhance the growth of metastasis [26,36], it is plausible
that early intervention of conventional cytotoxic agents
(anthracycline, cyclophosphamide, methotrexate, etc.)
would exert a better tumor suppressive effect. Compar-
ing with classic cytotoxic agents, taxanes are more ef-
fective on cells in division and growth since they are
microtubule inhibitors that bind reversibly to the sub-
unit of tubulin and lead to cell arrest at the G2/M
phase of the cell cycle. It is reasonable to speculate that
early initiation of taxane-containing chemotherapy may
be particularly effective on inhibiting the cancer cells in
mitotic phase caused by surgery stress.
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Our results demonstrate a significant adverse association
between waiting time to AC initiation and survival in
breast cancer. The results also provide further validation
of the intuitive concept of early time to AC after surgical
treatment. Physicians may need to give more careful con-
sideration to timing when discussing AC with patients,
and clinicians and jurisdictions need to optimize the pa-
tient flow logistics to minimize the interval from surgery
to AC.
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